Amneal Pharma Reports Positive Interim Results From Ongoing Phase 4 ELEVATE-PD Study
Amneal Pharmaceuticals announced positive interim results from its Phase 4 ELEVATE-PD study. The first 55 patients showed substantial clinical benefits after switching to CREXONT extended-release capsules, including increased Good On time and improved motor symptom control. Longer-term outcomes will be presented in 2026.
Add 
as your preferred news source on Google
Add Now
Amneal Pharmaceuticals, Inc. (AMRX) announced new positive interim results from its ongoing Phase 4 ELEVATE-PD study. The company said the first 55 patients evaluated after six weeks of treatment demonstrated substantial clinical benefit after switching to CREXONT extended-release capsules, including significant increases in daily Good On time, reductions in Off time, improved motor symptom control, and consistent gains in Good On time per doseregardless of whether patients switched from immediate-release carbidopa/levodopa, IR CD/LD with a COMT inhibitor, or RYTARY extended-release capsules.
Amneal will present longer-term outcomes and patient-reported results in 2026 as part of the ongoing, rolling ELEVATE-PD program.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
